NZ719078A - Compositions and methods for modulating farnesoid x receptors - Google Patents
Compositions and methods for modulating farnesoid x receptorsInfo
- Publication number
- NZ719078A NZ719078A NZ719078A NZ71907814A NZ719078A NZ 719078 A NZ719078 A NZ 719078A NZ 719078 A NZ719078 A NZ 719078A NZ 71907814 A NZ71907814 A NZ 71907814A NZ 719078 A NZ719078 A NZ 719078A
- Authority
- NZ
- New Zealand
- Prior art keywords
- receptors
- compositions
- methods
- farnesoid
- modulating farnesoid
- Prior art date
Links
- 102100038495 Bile acid receptor Human genes 0.000 title abstract 3
- 101150027485 NR1H4 gene Proteins 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361900013P | 2013-11-05 | 2013-11-05 | |
| PCT/US2014/063948 WO2015069666A1 (en) | 2013-11-05 | 2014-11-04 | Compositions and methods for modulating farnesoid x receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ719078A true NZ719078A (en) | 2018-07-27 |
Family
ID=51982773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ719078A NZ719078A (en) | 2013-11-05 | 2014-11-04 | Compositions and methods for modulating farnesoid x receptors |
Country Status (42)
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| PE20160682A1 (es) | 2013-11-05 | 2016-07-23 | Novartis Ag | Composiciones y metodos para modular los receptores x farnesoides |
| TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| JP6691552B2 (ja) * | 2015-04-30 | 2020-04-28 | ノバルティス アーゲー | ファルネソイドｘ受容体をモジュレートするのに有用である縮合三環式ピラゾール誘導体 |
| JP6986022B2 (ja) | 2016-02-22 | 2021-12-22 | ノバルティス アーゲー | Ｆｘｒアゴニストを使用するための方法 |
| CA3252823A1 (en) | 2016-06-13 | 2025-02-25 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| BR112018075734A2 (pt) | 2016-06-13 | 2019-04-02 | Gilead Sciences, Inc. | composto, composição farmacêutica, método para tratar um paciente com uma doença ou condição mediada pelo menos em parte por fxr, e, uso de um composto. |
| EP3512514A1 (en) * | 2016-09-14 | 2019-07-24 | Novartis AG | Novel regimes of fxr agonists |
| JOP20190040A1 (ar) * | 2016-09-14 | 2019-03-10 | Novartis Ag | توليفة من ناهضات fxr |
| AU2017339826A1 (en) * | 2016-10-05 | 2019-04-04 | Novartis Ag | Combination compositions comprising FXR agonists for treating or preventing a fibrotic,cirrhotic disease or disorder |
| CN107973790A (zh) * | 2016-10-22 | 2018-05-01 | 合帕吉恩治疗公司 | 杂环fxr调节剂 |
| JP6906626B2 (ja) | 2017-03-28 | 2021-07-21 | ギリアード サイエンシーズ， インコーポレイテッド | 肝疾患を処置するための治療的組み合わせ |
| KR102643558B1 (ko) * | 2017-06-05 | 2024-03-06 | 내셔널 유니버시티 오브 싱가포르 | 인간 트레포일 인자 3을 억제하는데 유용한 화합물 |
| MA49903A (fr) | 2017-08-15 | 2020-06-24 | Inflazome Ltd | Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 |
| UY37848A (es) | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
| WO2019034693A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| CN111093705A (zh) * | 2017-09-13 | 2020-05-01 | 诺华股份有限公司 | 包含fxr激动剂的组合 |
| SG11202003984UA (en) | 2017-11-09 | 2020-05-28 | Inflazome Ltd | Novel sulfonamide carboxamide compounds |
| US12221434B2 (en) | 2017-11-09 | 2025-02-11 | Inflazome Limited | Sulfonamide carboxamide compounds |
| CN110128432B (zh) * | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
| WO2019166619A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| JP7555327B2 (ja) | 2018-07-25 | 2024-09-24 | ノバルティス アーゲー | Ｎｌｒｐ３インフラマソーム阻害剤 |
| EA202191566A1 (ru) | 2019-01-15 | 2021-11-01 | Джилид Сайенсиз, Инк. | Соединения, модулирующие fxr (nr1h4) |
| US10610280B1 (en) | 2019-02-02 | 2020-04-07 | Ayad K. M. Agha | Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat |
| CN118388473A (zh) | 2019-02-19 | 2024-07-26 | 吉利德科学公司 | Fxr激动剂的固体形式 |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| AU2020312735A1 (en) | 2019-07-18 | 2021-12-16 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
| WO2021044351A1 (en) | 2019-09-06 | 2021-03-11 | Novartis Ag | Methods of treating liver disease using lta4h inhibitors |
| JP2023510274A (ja) | 2020-01-15 | 2023-03-13 | アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） | Ｄ型肝炎ウイルスによる感染を処置するためのｆｘｒアゴニストの使用 |
| CN113387828A (zh) * | 2020-03-14 | 2021-09-14 | 江巨东 | 一种阿利克仑中间体的制备方法 |
| WO2022037663A1 (zh) * | 2020-08-21 | 2022-02-24 | 苏州晶云药物科技股份有限公司 | 苯甲酸衍生物的新晶型及其制备方法 |
| JP2024502673A (ja) | 2021-01-14 | 2024-01-22 | ウエヌイグレックオ・ファーマ | Ｈｂｖ感染の処置のためのｆｘｒアゴニストとｉｆｎの相乗効果 |
| US20240216364A1 (en) | 2021-04-28 | 2024-07-04 | Enyo Pharma | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
| UY40374A (es) | 2022-08-03 | 2024-02-15 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
| CN120265284A (zh) * | 2022-08-26 | 2025-07-04 | 赛玛蒂克斯公司 | Fshr的新型调节剂及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050143449A1 (en) * | 2002-11-15 | 2005-06-30 | The Salk Institute For Biological Studies | Non-steroidal farnesoid X receptor modulators and methods for the use thereof |
| MX2008014854A (es) * | 2006-05-24 | 2008-12-05 | Lilly Co Eli | Antagonistas de fxr. |
| BRPI0716901B1 (pt) * | 2006-09-15 | 2020-04-22 | Thales Avionics Inc | sistema para transferir conteúdo e método para entregar conteúdo entre um veículo e outra entidade |
| TW200906823A (en) | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| PE20160682A1 (es) | 2013-11-05 | 2016-07-23 | Novartis Ag | Composiciones y metodos para modular los receptores x farnesoides |
| JP6691552B2 (ja) | 2015-04-30 | 2020-04-28 | ノバルティス アーゲー | ファルネソイドｘ受容体をモジュレートするのに有用である縮合三環式ピラゾール誘導体 |
-
2014
- 2014-11-04 PE PE2016000596A patent/PE20160682A1/es unknown
- 2014-11-04 SG SG11201603026PA patent/SG11201603026PA/en unknown
- 2014-11-04 AU AU2014346919A patent/AU2014346919B2/en not_active Ceased
- 2014-11-04 BR BR112016009630-4A patent/BR112016009630B1/pt not_active IP Right Cessation
- 2014-11-04 HR HRP20180817TT patent/HRP20180817T1/hr unknown
- 2014-11-04 DK DK14803001.8T patent/DK3065738T3/en active
- 2014-11-04 MX MX2016005865A patent/MX364834B/es active IP Right Grant
- 2014-11-04 LT LTEP14803001.8T patent/LT3065738T/lt unknown
- 2014-11-04 CN CN201480058975.8A patent/CN105682656B/zh not_active Expired - Fee Related
- 2014-11-04 EA EA201690930A patent/EA030430B1/ru not_active IP Right Cessation
- 2014-11-04 EP EP14803001.8A patent/EP3065738B1/en active Active
- 2014-11-04 ES ES14803001.8T patent/ES2670984T3/es active Active
- 2014-11-04 CU CU2016000063A patent/CU24375B1/es unknown
- 2014-11-04 RS RS20180524A patent/RS57179B1/sr unknown
- 2014-11-04 MA MA39088A patent/MA39088B1/fr unknown
- 2014-11-04 HU HUE14803001A patent/HUE039155T2/hu unknown
- 2014-11-04 MY MYPI2016701351A patent/MY175903A/en unknown
- 2014-11-04 KR KR1020167014613A patent/KR102350357B1/ko not_active Expired - Fee Related
- 2014-11-04 WO PCT/US2014/063948 patent/WO2015069666A1/en not_active Ceased
- 2014-11-04 AP AP2016009165A patent/AP2016009165A0/en unknown
- 2014-11-04 SI SI201430692T patent/SI3065738T1/en unknown
- 2014-11-04 US US15/034,280 patent/US9682939B2/en active Active
- 2014-11-04 CA CA2927705A patent/CA2927705C/en not_active Expired - Fee Related
- 2014-11-04 PT PT148030018T patent/PT3065738T/pt unknown
- 2014-11-04 NZ NZ719078A patent/NZ719078A/en not_active IP Right Cessation
- 2014-11-04 UY UY0001035818A patent/UY35818A/es not_active Application Discontinuation
- 2014-11-04 TN TN2016000143A patent/TN2016000143A1/en unknown
- 2014-11-04 TW TW103138253A patent/TWI662027B/zh not_active IP Right Cessation
- 2014-11-04 JP JP2016552453A patent/JP6424231B2/ja not_active Expired - Fee Related
- 2014-11-04 TR TR2018/07321T patent/TR201807321T4/tr unknown
- 2014-11-04 PL PL14803001T patent/PL3065738T3/pl unknown
- 2014-11-05 AR ARP140104163A patent/AR098316A1/es unknown
- 2014-11-05 JO JOP/2014/0318A patent/JO3454B1/ar active
-
2015
- 2015-03-17 NO NO15712554A patent/NO3105103T3/no unknown
-
2016
- 2016-04-14 ZA ZA2016/02555A patent/ZA201602555B/en unknown
- 2016-04-20 IL IL245242A patent/IL245242B/en active IP Right Grant
- 2016-04-25 CL CL2016000982A patent/CL2016000982A1/es unknown
- 2016-04-26 PH PH12016500777A patent/PH12016500777B1/en unknown
- 2016-05-05 GT GT201600085A patent/GT201600085A/es unknown
- 2016-05-05 CR CR20160212A patent/CR20160212A/es unknown
- 2016-05-05 SV SV2016005192A patent/SV2016005192A/es unknown
-
2017
- 2017-05-18 US US15/598,734 patent/US10077240B2/en active Active
-
2018
- 2018-05-24 CY CY20181100557T patent/CY1120273T1/el unknown
- 2018-08-07 US US16/056,881 patent/US10683271B2/en active Active
-
2020
- 2020-04-21 US US16/854,762 patent/US11021446B2/en not_active Expired - Fee Related
-
2021
- 2021-04-21 US US17/236,596 patent/US20210253534A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016500777B1 (en) | Compositions and methods for modulating farnesoid x receptors | |
| MY163216A (en) | Compositions and methods for modulating fxr | |
| PH12018500777A1 (en) | Farnesoid x receptor modulators | |
| EA201590200A1 (ru) | Модуляторы пути активации комплемента и их применение | |
| EA201490320A1 (ru) | Соединения тетрагидропиридопиридина и тетрагидропиридопиримидина и их применение в качестве модуляторов рецептора c5a | |
| MX2015005858A (es) | Moduladores del receptor acoplado a proteina g (gpr40) de dihidropirazol. | |
| EA201492023A1 (ru) | Регуляторы пути комплемента и их применение | |
| MY187886A (en) | 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators | |
| MX358499B (es) | Moduladores de dihidropirazol del receptor acoplado a la proteína g (gpr40). | |
| EA201492287A1 (ru) | Дейтерированные производные руксолитиниба | |
| EA201590118A1 (ru) | Производные пирролидина и их применение в качестве модуляторов пути активации комплемента | |
| MX2015005720A (es) | Moduladores de dihidropirazol de receptor acoplado a la proteina g (gpr40). | |
| EA201591805A1 (ru) | Оксабицикло [2.2.2] кислоты - модуляторы gpr120 | |
| EA201790496A1 (ru) | Соединения 1-алкил-6-оксо-1,6-дигидропиридин-3-ила и применение в качестве модуляторов sgrm | |
| SA521431274B1 (ar) | مشتق تتراهيدرو إيزوكينولين بديل كمعدِّل تفارغي إيجابي d1 | |
| EA201791397A1 (ru) | СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ | |
| EA201600166A1 (ru) | Производные пиперидина и азепина как модуляторы рецептора прокинетицина | |
| TN2013000241A1 (en) | Compositions and methods for modulating fxr | |
| MA40320A (fr) | Agent prophylactique ou thérapeutique pour des troubles du segment postérieur de l'œil |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 NOV 2020 BY CPA GLOBAL Effective date: 20191017 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 NOV 2021 BY CPA GLOBAL Effective date: 20201022 |
|
| LAPS | Patent lapsed |